<SEC-DOCUMENT>0001615774-18-001692.txt : 20180308
<SEC-HEADER>0001615774-18-001692.hdr.sgml : 20180308
<ACCEPTANCE-DATETIME>20180308160606
ACCESSION NUMBER:		0001615774-18-001692
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180308
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180308
DATE AS OF CHANGE:		20180308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35610
		FILM NUMBER:		18676489

	BUSINESS ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s109277_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B><BR>
<B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of Earliest Event Reported):
March 8, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Atossa Genetics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Delaware </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">001-35610 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">26-4753208</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of </FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">107 Spring Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Seattle, Washington</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">98104</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including
area code: (206)&nbsp;325-6086</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Not Applicable</U><BR>
Former name or former address, if changed since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item&nbsp;2.02. Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 8, 2018, Atossa Genetics Inc. (the &#8220;Company&#8221;)
issued a press release announcing 2017 financial results and a company update. A copy of the press release is attached as Exhibit
99.1 to this current report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 5pt 0 0"><I>The information in the report, including Exhibit 99.1 attached
hereto, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the
U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.<BR>
&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d)&nbsp;Exhibits</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press Release, dated March 8, 2018</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: March 8, 2018</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Atossa Genetics Inc.</FONT><BR>
<FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Kyle Guse&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Kyle Guse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Financial Officer, General Counsel and Secretary&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit&nbsp;Index</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="s109277_ex99-1.htm">99.1</A> </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="s109277_ex99-1.htm">Press Release, dated March 8, 2018</A></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s109277_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="img001_v1.jpg" ALT="(Atossa LOGO)">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Atossa
Genetics Announces</B>&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017
Financial Results and Provides Company Update</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEATTLE,
March 8, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other breast conditions, today announces 2017 financial results and provides
a Company update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Steve Quay, President and CEO, commented, &ldquo;In the later part of 2017, we completed a Phase 1 Study of our proprietary oral
and topical Endoxifen formulations, and we were pleased to report that all study objectives were met. We are now looking forward
to opening enrollment in two Phase 2 studies. One will use our oral Endoxifen to treat breast cancer patients who are not responding
to tamoxifen. Tamoxifen is the current FDA-approved standard of care for the approximately one million breast cancer survivors
to prevent a recurrence and new cancer. The second study will use our topical Endoxifen to determine if it can reduce a condition
called mammographic breast density, or MBD. Mammographic Breast Density is an independent risk factor for developing breast cancer.
It affects approximately 10 million women in the U.S. We are also planning to commence an additional study with topical Endoxifen
as well as a study using our intraductal microcatheters to deliver CAR-T or other immunotherapy,&rdquo; continued Dr. Quay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atossa&rsquo;s
important recent developments include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Successful
Phase 1 Study</I>. All objectives of Atossa&rsquo;s recent Phase 1 study of its proprietary oral and topical formulations of Endoxifen
were successfully met: there were no clinically significant safety signals and no clinically significant adverse events and both
the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were
detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen
levels that met or exceeded the published therapeutic level. &nbsp;The median time for patients in the study to reach the steady-state
serum levels of Endoxifen while taking daily doses of Atossa&rsquo;s oral Endoxifen was 7 days. Published literature indicates
that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TRAP
CAR-T Program</I>. In October 2017, we announced that we are developing a novel method to deliver CAR-T cells into the ducts of
the breast for the potential targeted treatment of breast cancer. This approach uses our proprietary intraductal microcatheter
technology for the potential transpapillary, or &ldquo;TRAP,&rdquo; delivery of either T-cells that have been genetically modified
to attack breast cancer cells or various immunotherapies. We believe this method has several potential advantages including the
reduction of toxicity by limiting systemic exposure of the T-cells or immunotherapy; improved efficacy by placing the T-cells
or immunotherapy in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and,
lymphatic migration of the CAR-T cells or immunotherapy potentially extending their cytotoxic actions into the regional lymph
system, which could limit tumor cell dissemination. Our approach is in the R&amp;D stage and is currently not FDA approved.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expansion
of Scientific Advisory Board</I>. At the end of 2017, we added Dr. Carl Novina to our Scientific Advisory Board. Together with
Dr. Jack Cuzick, we now have a world-renowned group advising on the scientific and medical aspects or our programs.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Capital
Raising Activity</I>. In 2017, we made significant improvements to our balance sheet by raising approximately $12 million in capital,
which strengthened our balance sheet and improved our stockholder base with the addition of institutional biotech-focused investors.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Atossa&rsquo;s
2018 potential milestones include:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
half of 2018 - opening the Phase 2 Study of topical Endoxifen to treat MBD at Stockholm South General Hospital in Sweden (which
we plan to complete in 2018).</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
half of 2018 - opening the Phase 2 Study of oral Endoxifen to treat patients who are not responding to Tamoxifen (which we plan
to complete in 2018).</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
half of 2018 - commencing one or more studies to demonstrate safety and efficacy of administering TRAP CAR-T or another immunotherapy
with our microcatheters.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
2018:</FONT></TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
additional opportunities for our Endoxifen formulations; and</FONT></TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continuing
our Phase 2 study administering Fulvestrant with our microcatheters.</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Breast
Cancer Statistics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States
this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American
women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk
of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will
die from breast cancer in 2017.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017
Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue
and Cost of Revenue: </I>For the years ended December 31, 2017 and 2016, we have no source of sustainable revenue and no associated
cost of revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Expenses</I>: Total operating expenses were $7,649,171 for the year ended December 31, 2017, which is a decrease of $319,419 or
4.0%, from the year ended December 31, 2016. Operating expenses for 2017 consisted of general and administrative (G&amp;A) expenses
of $4,859,369, R&amp;D expenses of $2,328,087, and impairment of our Acueity intangible assets of $461,715.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I>: G&amp;A expenses were $4,859,369 for the year ended December 31, 2017, a decrease of $1,619,824,
or 25.0% from the total G&amp;A expenses for the year ended December 31, 2016 of $6,479,193. G&amp;A expenses consist primarily
of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The
2017 decrease in G&amp;A expense was primarily attributable to a reduction in payroll expenses resulting from deceased headcount,
rent and exit costs incurred in 2016. At the beginning of 2016, our strategy shifted away from commercialization of medical devices
towards focusing exclusively on development of our pharmaceutical and microcatheter candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I>: R&amp;D expenses for the year ended December 31, 2017, were $2,328,087, an increase of $1,557,660,
or 202% from R&amp;D expenses in 2016 of $770,427. The increase in R&amp;D expenses is attributed to salaries, manufacturing,
and clinical trial expenses associated with our Endoxifen program for which manufacturing commenced at the beginning of 2017 and
the clinical studies commenced in mid-2017. We expect our R&amp;D expenses to increase throughout 2018 as we commence Phase 2
clinical studies of Endoxifen, continue the clinical trial of fulvestrant administered via our microcatheters and as we continue
the development of other indications and therapeutics, including CAR-T and immunotherapies administered via our intraductal microcatheters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
and Cash Equivalents</I>: As of December 31, 2017, the Company had approximately $7.2 million in cash and cash equivalents and
working capital of approximately $6.7 million.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Atossa Genetics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atossa
Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer
and other breast conditions. For more information, please visit www.atossagenetics.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that
may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties
associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or
timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, preliminary and final results
of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations
and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights,
and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without
limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atossa
Genetics Company Contact:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atossa
Genetics Inc.<BR>
Kyle Guse<BR>
CFO and General Counsel<BR>
(866) 893-4927<BR>
&nbsp;kyle.guse@atossagenetics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations Contact:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
Gordon<BR>
CoreIR<BR>
377 Oak Street<BR>
Concourse 2<BR>
Garden City, NY 11530<BR>
Office: 516.222.2560<BR>
scottg@CoreIR.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATOSSA
GENETICS INC.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As&nbsp;of&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><U>Assets</U></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,217,469</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,027,962</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,601</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development tax rebate receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">358,277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,344</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,898,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,254,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Furniture and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,467</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">640,440</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">178,907</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">194,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,164,094</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,372</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">334,901</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">254,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,964</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Payroll liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">784,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,899</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,534</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,083</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,225,407</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,047,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 16.2pt">Preferred stock - $.001 par value; 10,000,000 shares authorized, no shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 16.2pt">Common stock - $.015 par value; 75,000,000 shares authorized, 31,822,741 and 3,786,913 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">477,342</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,804</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 16.2pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,887,674</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,344,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 16.2pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(65,426,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57,303,748</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total stockholders' equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,938,687</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,097,106</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,164,094</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,372</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATOSSA
GENETICS INC.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,328,087</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">770,427</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,859,369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,479,193</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Impairment of intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">461,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">718,970</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 19.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,649,171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,968,590</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,649,171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,968,590</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of common stock warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(280,747</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant financing expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(192,817</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">154</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,599,705</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,122,581</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,368,885</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,122,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,368,885</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deemed dividend attributable to Series A preferred stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,568,132</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,690,713</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,368,885</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss per common share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.91</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,697,273</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,947,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X10N17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    ;    <@$R  (    4    C8=I  0    !    I    -    !(
M 0   $@    !061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W, ,C Q.#HP,SHP
M." R,3HU-3HT,        Z !  ,    !__\  * "  0    !    R* #  0
M   !    20         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !+X
M     $@    !    2     '_V/_@ !!*1DE&  $" 0!( $@  /_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ .@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M (7Q&;:_I^WW?SG^#6+EN9T^\9?6G#JO77-#F8KG31C ^YGK[/9O_P"!K_\
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MW=8\_2>[\Y)1K2GEZ[_K39UF_HG[38,BC IRA>:&;3<YYKM8YO\ W'=L]O\
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M]U;LFMGJ5LM?0R_TO424*LV__]*N:;Y/Z&WG_1O_ /(IC1>1!HM@_P#!O_\
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M[_2_[3?SJJYG5.JU=;SZ:<JQWH7X3</#-;7-L%\?;*]PK]78QGZ3U_5_5?\
M"_H_T:ZQ))/7IL'_V?_M&-90:&]T;W-H;W @,RXP #A"24T$)0      $
M                   X0DE- ^T      !  2     $  0!(     0 !.$))
M300F       .             #^    X0DE-! T       0    >.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-! H       $
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T<    &              !)    R     D :0!M
M &< ,  P #$ 7P!V #$    !                          $
M     ,@   !)                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   !)     %)G:'1L;VYG    R     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    20    !2
M9VAT;&]N9P   ,@    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    !/_         X0DE-!!$       $! #A"24T$
M%       !     $X0DE-! P     $Q0    !    H    #H   '@  !LP
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M ', : !O '     2 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
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MT[AH<CY%ELVU^O<-(=,+12"2B0%N2ONK+J&#U)7+LB;!;[.&*_47KEN/PIP
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M;QWPH([85K(]0@IY$@$U^P=$FW=_/(VWT=N;9&-^6GPG^6'Q;VGV$#)MW?\
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M[3K<^V[<115&>C\0DQU'%7RQ)-(498TF$K62Y#"?$.I0WN";<>6 MK$7E90
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MD^PJ-9LO3[E_A>Y<7C:Z/*U4D:4C0^ B]FU-[WD]'NV[)8WNTW^XL9S-"<A
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MHQ.7K,@*O"03(E;'4T\(1Y%\;2 DC7ET?\U2V=QN;W=I?)(LAX 'R'ET(O\
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#=?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
